Prostate cancer patients treated with second-generation antiandrogens may have an increased risk of falls, fatigue, and cognitive toxicity.
Cancer death rates in the US have declined in recent years, but the declines vary by congressional district, a study suggests.
Investigators report results from the phase 3 randomized EMBARK trial.
Findings suggest link to more aggressive disease among estrogen users, but researchers say larger studies needed.
Investigators analyzed survey results from 495 patients with newly diagnosed localized prostate cancer.